HEALIOS K.K. Logo

HEALIOS K.K.

Clinical-stage biotech developing regenerative medicine and cell-based therapies.

4593 | T

Overview

Corporate Details

ISIN(s):
JP3835100003
LEI:
Country:
Japan
Address:
千代田区有楽町一丁目7番1号

Description

Healios K.K. is a clinical-stage biotechnology company specializing in the research and development of regenerative medicine and cell-based therapies. The company's pipeline is focused on addressing unmet medical needs in multiple therapeutic areas. Its lead programs include an allogeneic stem cell product in late-stage clinical development for ischemic stroke and Acute Respiratory Distress Syndrome (ARDS). Healios also leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop next-generation treatments. This platform includes retinal pigment epithelium (RPE) cells for age-related macular degeneration and engineered natural killer (eNK) cells designed to target solid tumors. A key area of its research is the creation of Universal Donor Cells (UDCs) to produce hypoimmunogenic therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-08-13 05:35
確認書
Japanese ZIP 8.2 KB
2025-08-13 05:34
半期報告書-第15期(2025/01/01-2025/12/31)
Japanese ZIP 436.9 KB
2025-05-13 08:33
臨時報告書
Japanese ZIP 19.7 KB
2025-03-27 07:22
臨時報告書
Japanese ZIP 25.4 KB
2025-03-27 07:21
確認書
Japanese ZIP 8.1 KB
2025-03-27 07:20
内部統制報告書-第14期(2024/01/01-2024/12/31)
Japanese ZIP 21.7 KB
2025-03-27 07:19
有価証券報告書-第14期(2024/01/01-2024/12/31)
Japanese ZIP 2.0 MB
2025-02-14 05:13
訂正臨時報告書
Japanese ZIP 37.5 KB
2025-02-14 04:07
臨時報告書
Japanese ZIP 21.3 KB
2025-01-27 07:31
有価証券届出書(参照方式)
Japanese ZIP 224.3 KB
2025-01-22 07:33
臨時報告書
Japanese ZIP 53.3 KB
2024-11-13 07:34
臨時報告書
Japanese ZIP 20.0 KB
2024-08-13 08:04
臨時報告書
Japanese ZIP 19.9 KB
2024-08-13 08:04
確認書
Japanese ZIP 8.2 KB
2024-08-13 08:03
半期報告書-第14期(2024/01/01-2024/12/31)
Japanese ZIP 402.0 KB

Automate Your Workflow. Get a real-time feed of all HEALIOS K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEALIOS K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEALIOS K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.